Navigation Links
New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
Date:10/12/2011

BOSTON, Oct. 12, 2011 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a podcast series with experience-rich perspectives on topics throughout the clinical development and commercialization lifecycle. PAREXEL "Insights 1 to 1" podcasts are conversations with thought leaders from PAREXEL designed to inform listeners about advanced approaches for biopharmaceutical companies to accomplish their goals. These experts discuss key challenges impacting the industry and emerging opportunities for biopharmaceutical companies and their CRO partners.  

The first podcast in the series entitled "Four growth-driving partnership activities" features a two-part interview with Josh Schultz, Vice President and Strategic Account Leader, PAREXEL, who focuses on how biopharmaceutical companies can define and design optimal strategic relationships to realize value, gain the greatest advantages, and produce results.  Other podcasts currently scheduled in the series will address:

  • Creating greater efficiency through the integration of eClinical technology and clinical processes
  • Understanding the eCRO role and how it represents a major shift in clinical research practice
  • Optimizing clinical development programs designed for commercial success

  • To listen to valuable conversations with experts about biopharmaceutical development and commercialization best practices and to subscribe to the podcast series visit: http://www.PAREXEL.com/news-and-events/podcasts/subscribe/. The podcasts can be accessed via streaming audio, or can be downloaded onto a media player.

    About PAREXEL InternationalPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,550 employees. For more information about PAREXEL International visit www.PAREXEL.com.

    This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $18 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 as filed with the SEC on August 26, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

    PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.Contacts:Jennifer Baird, Senior Director of Public RelationsKim Leadley /Gene CarozzaPAREXEL InternationalPAN CommunicationsTel: +781-434-4409Tel: + 617-502-4300Email: Jennifer.Baird@PAREXEL.comEmail: PAREXEL@pancomm.com
    '/>"/>

    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
    2. PAREXEL Expands Global Clinical Pharmacology Capabilities
    3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
    4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
    5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
    6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
    7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
    8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
    9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
    10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
    11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/18/2017)... , Jan. 18, 2017  Tarix Orphan LLC ... has granted a Rare Pediatric Disease (RPD) designation for ... Recessive Dystrophic Epidermolysis Bullosa (RDEB), a rare genetic skin ... and treatment is limited to supportive care. ... Orphan Drug Designation previously granted by the FDA in ...
    (Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
    (Date:1/17/2017)... DUBLIN , Jan 17, 2017 Research ... Pancreas Devices System Market 2016-2020" report to their offering. ... The global artificial ... during the period 2016-2020. Global Artificial Pancreas Devices System ... with inputs from industry experts. The report covers the market landscape ...
    Breaking Medicine Technology:
    (Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
    (Date:1/18/2017)... ... 2017 , ... The Hear the World Foundation, a Sonova ... of cochlear implants. In February 2017, the first three children with profound hearing ... leading an independent life. This engagement builds on the support the Hear the ...
    (Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now ... in the corners and commit the crime of stalking, a very real danger to many ... often overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. Stop ...
    (Date:1/17/2017)... ... January 17, 2017 , ... For breast cancer clinicians and ... or those who desire a more intimate review and analysis of its highlights, a ... to Bedside—is being offered by Imedex on February 4, 2017 in Chicago. Chaired by ...
    (Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks from ... campaigns regarding the topic of Beauty and Personal Care. , Everyone ... better way to commit to these changes than beginning with personal care and beauty ...
    Breaking Medicine News(10 mins):